| Autor: |
Stanton, L., Cole, A., Keyworth, N., Collins, G. P, McKay, P., Smith, P., Radhakrishnan, V., Konn, Z., Irvine, N., Coleman, A., Stuart, C., Hatchard, P., Longman, K., Philip, D. M., Caddy, J., Davies, A. J |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p841-842, 2p |
| Abstrakt: |
P+R-ICE: PEMBROLIZUMAB IN COMBINATION WITH R-ICE CHEMOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - ONGOING TRIAL The P+R-ICE trial aims to evaluate the activity of a novel agent pembrolizumab in addition to the current best available treatment (R-ICE) for relapsed refractory DLBCL patients who are fit for autologous stem cell transplant (ASCT). B Introduction: b Approximately one third of patients with diffuse large B-cell lymphoma (DLBCL) have disease which either fails to respond to initial chemo-immunotherapy, or relapses after initial remission. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text